全文获取类型
收费全文 | 4472篇 |
免费 | 451篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 60篇 |
儿科学 | 95篇 |
妇产科学 | 147篇 |
基础医学 | 519篇 |
口腔科学 | 88篇 |
临床医学 | 479篇 |
内科学 | 974篇 |
皮肤病学 | 54篇 |
神经病学 | 359篇 |
特种医学 | 85篇 |
外国民族医学 | 1篇 |
外科学 | 671篇 |
综合类 | 80篇 |
一般理论 | 1篇 |
预防医学 | 390篇 |
眼科学 | 179篇 |
药学 | 207篇 |
中国医学 | 3篇 |
肿瘤学 | 544篇 |
出版年
2022年 | 36篇 |
2021年 | 80篇 |
2020年 | 61篇 |
2019年 | 75篇 |
2018年 | 79篇 |
2017年 | 74篇 |
2016年 | 80篇 |
2015年 | 89篇 |
2014年 | 108篇 |
2013年 | 144篇 |
2012年 | 209篇 |
2011年 | 225篇 |
2010年 | 120篇 |
2009年 | 103篇 |
2008年 | 203篇 |
2007年 | 199篇 |
2006年 | 199篇 |
2005年 | 193篇 |
2004年 | 185篇 |
2003年 | 197篇 |
2002年 | 171篇 |
2001年 | 148篇 |
2000年 | 160篇 |
1999年 | 151篇 |
1998年 | 50篇 |
1997年 | 41篇 |
1996年 | 29篇 |
1995年 | 31篇 |
1994年 | 38篇 |
1993年 | 39篇 |
1992年 | 106篇 |
1991年 | 103篇 |
1990年 | 100篇 |
1989年 | 95篇 |
1988年 | 85篇 |
1987年 | 77篇 |
1986年 | 76篇 |
1985年 | 76篇 |
1984年 | 54篇 |
1983年 | 50篇 |
1982年 | 48篇 |
1981年 | 35篇 |
1979年 | 39篇 |
1978年 | 30篇 |
1977年 | 35篇 |
1975年 | 33篇 |
1974年 | 32篇 |
1973年 | 44篇 |
1972年 | 34篇 |
1969年 | 40篇 |
排序方式: 共有4936条查询结果,搜索用时 203 毫秒
91.
92.
93.
94.
95.
Joseph R. Scalea Shoshana T. Levi Winston Ally Kenneth L. Brayman 《Expert Review of Clinical Immunology》2016,12(3):333-342
Since its introduction to the antirejection armamentarium in 1994, tacrolimus has become the workhorse of transplant professionals for avoidance of solid organ transplant rejection. Not only does tacrolimus have potent immunosuppressive qualities that prevent rejection, but dosing is straight forward and it is generally well tolerated. However, in the long term, conditions such as calcineurin inhibitor nephrotoxicity can become a problem. A discussion of the compound, the pharmacokinetics, history, and current approved uses for tacrolimus is described. Indeed, tacrolimus is the most important drug for preventing transplant rejection. However, the increased appreciation for significant side effects, particularly in the long term, has led to building interest in new agents with different mechanisms of action and different metabolism. 相似文献
96.
97.
Investigations into the role of microRNA (miRNA) in hepatitis C virus (HCV) infection, disease pathogenesis and host immune and treatment response have potential to produce innovations in diagnosis, prognosis and therapy. However, investigational challenges remain in generating clinically useful and reproducible results. We review the literature with a primary emphasis on methods and technologies used to construct our current understanding of miRNA and HCV disease. A second emphasis is to understand potential clinical research applications and provide clarification of previous study results. Many miRNA have key roles in viral and immunopathogenesis of HCV infection across multiple tissue compartments. Controversy exists among published studies regarding relative measurements, temporal changes and biological significance of specific miRNA and HCV infection. To reconcile diverging data, additional research into optimal sample processing, in vitro models, techniques for microarray differential expression of miRNAs, practices for sample result normalization, and effect of HCV genotype variation on expression are all necessary. Microarray and miRNA isolation techniques should be selected based on ability to generate reproducible results in the sample type of interest. More direct comparisons of efficacy and reliability of various multiplex microarrays and an improved consensus around miRNA normalization and quantitation are necessary so that data can be compared across studies. 相似文献
98.
Assi Levi Dan Ben Amitai Daniel Mimouni Yael A. Leshem Ofir Arzi Moshe Lapidoth 《Lasers in medical science》2018,33(3):597-601
The verrucous epidermal nevus (VEN) is the most common type of epidermal nevi. As lesions can be disfiguring, treatment is often sought. Many therapeutic approaches have been reported, with variable efficacy and safety. Picosecond (PS) lasers are novel laser devices designated to target small chromophores. A side effect of these lasers is blistering due to epidermal-dermal separation. We aimed to harness this side effect of the PS lasers to treat patients with VEN. The purpose of this study was to report our experience treating VEN using a PS 532-nm laser. We present a retrospective case series of six patients with large VEN who were treated using a PS 532-nm laser (2–6 treatments, 8–10 weeks apart). Response in clinical photographs was assessed by two independent dermatologists and graded on a scale of 0 (exacerbation) to 4 (76–100% improvement). Patient satisfaction was recorded on a scale of 1–5. All patients demonstrated significant improvement. Average improvement was 3.7 on the quartile scale of improvement. Patient satisfaction rate averaged 4.7. The PS 532-nm laser is a promising novel modality for the treatment of large VEN. 相似文献
99.
100.